The C5a/C5a receptor 1 axis controls tissue neovascularization through CXCL4 release from platelets.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
07 06 2021
07 06 2021
Historique:
received:
09
06
2019
accepted:
28
03
2021
entrez:
8
6
2021
pubmed:
9
6
2021
medline:
23
6
2021
Statut:
epublish
Résumé
Platelets contribute to the regulation of tissue neovascularization, although the specific factors underlying this function are unknown. Here, we identified the complement anaphylatoxin C5a-mediated activation of C5a receptor 1 (C5aR1) on platelets as a negative regulatory mechanism of vessel formation. We showed that platelets expressing C5aR1 exert an inhibitory effect on endothelial cell functions such as migration and 2D and 3D tube formation. Growth factor- and hypoxia-driven vascularization was markedly increased in C5ar1
Identifiants
pubmed: 34099640
doi: 10.1038/s41467-021-23499-w
pii: 10.1038/s41467-021-23499-w
pmc: PMC8185003
doi:
Substances chimiques
Angiogenesis Inducing Agents
0
C5ar1 protein, mouse
0
Cxcr3 protein, mouse
0
Receptor, Anaphylatoxin C5a
0
Receptors, CXCR3
0
Platelet Factor 4
37270-94-3
Complement C5a
80295-54-1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3352Références
Ricklin, D. & Lambris, J. D. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J. Immunol. 190, 3831–3838 (2013).
pubmed: 23564577
doi: 10.4049/jimmunol.1203487
Alawieh, A., Elvington, A. & Tomlinson, S. Complement in the homeostatic and ischemic brain. Front. Immunol. 6, 417 (2015).
pubmed: 26322048
pmcid: 4533015
doi: 10.3389/fimmu.2015.00417
Staab, E. B., Sanderson, S. D., Wells, S. M. & Poole, J. A. Treatment with the C5a receptor/CD88 antagonist PMX205 reduces inflammation in a murine model of allergic asthma. Int. Immunopharmacol. 21, 293–300 (2014).
pubmed: 24859057
pmcid: 4108528
doi: 10.1016/j.intimp.2014.05.008
Begieneman, M. P. et al. Myocardial infarction induces atrial inflammation that can be prevented by C1-esterase inhibitor. J. Clin. Pathol. 69, 1093–1099 (2016).
pubmed: 27153875
doi: 10.1136/jclinpath-2016-203639
Lu, F., Fernandes, S. M. & Davis, A. E. The effect of C1 inhibitor on myocardial ischemia and reperfusion injury. Cardiovasc. Pathol. 22, 75–80 (2013).
pubmed: 22705194
doi: 10.1016/j.carpath.2012.05.003
Kolev, M., Friec, G. L. & Kemper, C. Complement-tapping into new sites and effector systems. Nat. Rev. Immunol. 14, 811–820 (2014).
pubmed: 25394942
doi: 10.1038/nri3761
Leslie, M. The new view of complement. Science 337, 1034–1037 (2012).
pubmed: 22936752
doi: 10.1126/science.337.6098.1034
Verschoor, A., Karsten, C. M., Broadley, S. P., Laumonnier, Y. & Köhl, J. Old dogs—new tricks: immunoregulatory properties of C3 and C5 cleavage fragments. Immunol. Rev. 274, 112–126 (2016).
pubmed: 27782330
doi: 10.1111/imr.12473
Nozaki, M. et al. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc. Natl Acad. Sci. USA 103, 2328–2333 (2006).
pubmed: 16452172
doi: 10.1073/pnas.0408835103
pmcid: 1413680
Girardi, G., Yarilin, D., Thurman, J. M., Holers, V. M. & Salmon, J. E. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J. Exp. Med. 203, 2165–2175 (2006).
pubmed: 16923853
pmcid: 2118387
doi: 10.1084/jem.20061022
Rafail, S. et al. Complement deficiency promotes cutaneous wound healing in mice. J. Immunol. 194, 1285–1291 (2015).
pubmed: 25548229
doi: 10.4049/jimmunol.1402354
Langer, H. F. et al. Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis. Blood 116, 4395–4403 (2010).
pubmed: 20625009
pmcid: 2996109
doi: 10.1182/blood-2010-01-261503
van Lookeren Campagne, M., Strauss, E. C. & Yaspan, B. L. Age-related macular degeneration: complement in action. Immunobiology 221, 733–739 (2016).
pubmed: 26742632
doi: 10.1016/j.imbio.2015.11.007
Gawaz, M. & Geisler, T. Platelet activity: an obstacle for successful PCI. Nat. Rev. Cardiol. 6, 391–392 (2009).
pubmed: 19471282
doi: 10.1038/nrcardio.2009.76
Ruggeri, Z. M. et al. Unravelling the mechanism and significance of thrombin binding to platelet glycoprotein Ib. Thromb. Haemost. 104, 894–902 (2010).
pubmed: 20941453
doi: 10.1160/TH10-09-0578
Nording, H. M., Seizer, P. & Langer, H. F. Platelets in inflammation and atherogenesis. Front. Immunol. 6, 3378–3384 (2015).
doi: 10.3389/fimmu.2015.00098
Langer, H. F. & Chavakis, T. Leukocyte - endothelial interactions in inflammation. J. Cell. Mol. Med. 13, 1211–1220 (2009).
pubmed: 19538472
pmcid: 2861890
doi: 10.1111/j.1582-4934.2009.00811.x
Patzelt, J. & Langer, H. F. Platelets in angiogenesis. Curr. Vasc. Pharmacol. 10, 570–577 (2012).
pubmed: 22338572
doi: 10.2174/157016112801784648
Huo, Y. et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat. Med. 9, 61–67 (2003).
pubmed: 12483207
doi: 10.1038/nm810
Verschoor, A. & Langer, H. F. Crosstalk between platelets and the complement system in immune protection and disease. Thromb. Haemost. 110, 910–919 (2013).
pubmed: 24008927
doi: 10.1160/TH13-02-0102
Martel, C. et al. Requirements for membrane attack complex formation and anaphylatoxins binding to collagen-activated platelets. PLoS ONE 6, e18812 (2011).
pubmed: 21526204
pmcid: 3078139
doi: 10.1371/journal.pone.0018812
Patzelt, J. et al. Expression of anaphylatoxin receptors on platelets in patients with coronary heart disease. Atherosclerosis 238, 289–295 (2015).
pubmed: 25544179
doi: 10.1016/j.atherosclerosis.2014.12.002
Sauter, R. et al. Anaphylatoxin receptor C3aR contributes to platelet function, thrombus formation and in vivo haemostasis. Thromb. Haemost. 119, 179–182 (2019).
pubmed: 30597512
doi: 10.1055/s-0038-1676349
Sauter, R. J. et al. Functional relevance of the anaphylatoxin receptor C3aR for platelet function and arterial thrombus formation marks an intersection point between innate immunity and thrombosis. Circulation 138, 1720–1735 (2018).
pubmed: 29802205
pmcid: 6202244
doi: 10.1161/CIRCULATIONAHA.118.034600
Chatterjee, M. et al. Distinct platelet packaging, release, and surface expression of proangiogenic and antiangiogenic factors on different platelet stimuli. Blood 117, 3907–3911 (2011).
pubmed: 21330475
doi: 10.1182/blood-2010-12-327007
Battinelli, E. M., Markens, B. A. & Italiano, J. E. Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood 118, 1359–1369 (2011).
pubmed: 21680800
pmcid: 3152500
doi: 10.1182/blood-2011-02-334524
Italiano, J. E. et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet α granules and differentially released. Blood 111, 1227–1233 (2008).
pubmed: 17962514
pmcid: 2214735
doi: 10.1182/blood-2007-09-113837
Economopoulou, M. et al. Histone H2AX is integral to hypoxia-driven neovascularization. Nat. Med. 15, 553–558 (2009).
pubmed: 19377486
pmcid: 2713773
doi: 10.1038/nm.1947
Feng, W. et al. A novel role for platelet secretion in angiogenesis: mediating bone marrow-derived cell mobilization and homing. Blood 117, 3893–3902 (2011).
pubmed: 21224474
pmcid: 3083301
doi: 10.1182/blood-2010-08-304808
Karsten, C. M. et al. Monitoring and cell-specific deletion of C5aR1 using a novel floxed GFP-C5aR1 reporter knock-in mouse. J. Immunol. 194, 1841–1855 (2015).
pubmed: 25589074
doi: 10.4049/jimmunol.1401401
Tiedt, R., Schomber, T., Hao-Shen, H. & Skoda, R. C. Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo. Blood 109, 1503–1506 (2007).
pubmed: 17032923
doi: 10.1182/blood-2006-04-020362
Bergmann, C. E. et al. Arteriogenesis depends on circulating monocytes and macrophage accumulation and is severely depressed in op/op mice. J. Leukoc. Biol. 80, 59–65 (2006).
pubmed: 16684892
doi: 10.1189/jlb.0206087
Simons, M. & Eichmann, A. Molecular controls of arterial morphogenesis. Circ. Res. 116, 1712–1724 (2015).
pubmed: 25953926
pmcid: 4509635
doi: 10.1161/CIRCRESAHA.116.302953
Karsten, C. M. et al. Monitoring C5aR2 expression using a floxed tdTomato-C5aR2 knock-in mouse. J. Immunol. 199, 3234–3248 (2017).
pubmed: 28864475
doi: 10.4049/jimmunol.1700710
Struyf, S. et al. Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3. Blood 117, 480–488 (2011).
pubmed: 20980681
pmcid: 3031477
doi: 10.1182/blood-2009-11-253591
Hartwig, H. et al. Platelet-derived PF4 reduces neutrophil apoptosis following arterial occlusion. Thromb. Haemost. 111, 562–564 (2013).
pubmed: 24258616
Etulain, J. et al. Control of angiogenesis by galectins involves the release of platelet-derived proangiogenic factors. PLoS ONE 9, e96402 (2014).
pubmed: 24788652
pmcid: 4005776
doi: 10.1371/journal.pone.0096402
Zaslavsky, A. et al. Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood 115, 4605–4613 (2010).
pubmed: 20086246
pmcid: 2881490
doi: 10.1182/blood-2009-09-242065
Kisucka, J. et al. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc. Natl Acad. Sci. USA 103, 855–860 (2006).
pubmed: 16418262
doi: 10.1073/pnas.0510412103
pmcid: 1348013
Packham, I. M., Watson, S. P., Bicknell, R. & Egginton, S. In vivo evidence for platelet-induced physiological angiogenesis by a COX driven mechanism. PLoS ONE 9, e107503 (2014).
pubmed: 25238071
pmcid: 4169573
doi: 10.1371/journal.pone.0107503
Stellos, K. et al. Platelets in regeneration. Semin. Thromb. Hemost. 36, 175–184 (2010).
pubmed: 20414833
doi: 10.1055/s-0030-1251502
Klement, G. L. et al. Platelets actively sequester angiogenesis regulators. Blood 113, 2835–2842 (2009).
pubmed: 19036702
doi: 10.1182/blood-2008-06-159541
Rutkowski, M. J., Sughrue, M. E., Kane, A. J., Mills, S. A. & Parsa, A. T. Cancer and the complement cascade. Mol. Cancer Res. 8, 1453–1465 (2010).
pubmed: 20870736
doi: 10.1158/1541-7786.MCR-10-0225
Nording, H. & Langer, H. F. Complement links platelets to innate immunity. Semin. Immunol. 37, 43–52 (2018).
pubmed: 29426568
doi: 10.1016/j.smim.2018.01.003
Peterson, J. E. et al. VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis 15, 265–273 (2012).
pubmed: 22402885
doi: 10.1007/s10456-012-9259-z
Radziwon-Balicka, A., Moncada de la Rosa, C., Zielnik, B., Doroszko, A. & Jurasz, P. Temporal and pharmacological characterization of angiostatin release and generation by human platelets: implications for endothelial cell migration. PLoS ONE 8, e59281 (2013).
pubmed: 23555012
pmcid: 3598756
doi: 10.1371/journal.pone.0059281
Ma, L. et al. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc. Natl Acad. Sci. USA 102, 216–220 (2005).
pubmed: 15615851
doi: 10.1073/pnas.0406682102
Egan, K. et al. Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells. PLoS ONE 6, e26125 (2011).
pubmed: 22022533
pmcid: 3192146
doi: 10.1371/journal.pone.0026125
Bir, S. C. et al. Angiogenic properties of sustained release platelet-rich plasma: characterization in-vitro and in the ischemic hind limb of the mouse. J. Vasc. Surg. 50, 870–879 (2009).
pubmed: 19679427
doi: 10.1016/j.jvs.2009.06.016
Noris, M. & Remuzzi, G. Overview of complement activation and regulation. Semin. Nephrol. 33, 479–492 (2013).
pubmed: 24161035
pmcid: 3820029
doi: 10.1016/j.semnephrol.2013.08.001
Carlomosti, F. et al. Oxidative stress-induced miR-200c disrupts the regulatory loop among SIRT1, FOXO1, and eNOS. Antioxid. Redox Signal. 27, 328–344 (2017).
pubmed: 27960536
doi: 10.1089/ars.2016.6643
Ghebrehiwet, B., CebadaMora, C., Tantral, L., Jesty, J. & Peerschke, E. I. B. gC1qR/p33 serves as a molecular bridge between the complement and contact activation systems and is an important catalyst in inflammation. Adv. Exp. Med. Biol. 586, 95–105 (2006).
Yin, W., Ghebrehiwet, B., Weksler, B. & Peerschke, E. I. Classical pathway complement activation on human endothelial cells. Mol. Immunol. 44, 2228–2234 (2007).
pubmed: 17173972
doi: 10.1016/j.molimm.2006.11.012
Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 438, 932–936 (2005).
pubmed: 16355210
doi: 10.1038/nature04478
Bora, P. S. et al. Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. J. Immunol. 174, 491–497 (2005).
pubmed: 15611275
doi: 10.4049/jimmunol.174.1.491
Thurman, J. M. et al. Oxidative stress renders retinal pigment epithelial cells susceptible to complement-mediated injury. J. Biol. Chem. 284, 16939–16947 (2009).
pubmed: 19386604
pmcid: 2719331
doi: 10.1074/jbc.M808166200
Bikfalvi, A. Platelet factor 4: an inhibitor of angiogenesis. Semin. Thromb. Hemost. 30, 379–385 (2004).
pubmed: 15282661
doi: 10.1055/s-2004-831051
Myler, H. A. & West, J. L. Heparanase and platelet factor-4 induce smooth muscle cell proliferation and migration via bFGF release from the ECM. J. Biochem. 131, 913–922 (2002).
pubmed: 12038989
doi: 10.1093/oxfordjournals.jbchem.a003182
Eslin, D. E. et al. Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin. Blood 104, 3173–3180 (2004).
pubmed: 14764524
doi: 10.1182/blood-2003-11-3994
Slungaard, A. et al. Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. Blood 102, 146–151 (2003).
pubmed: 12609838
doi: 10.1182/blood-2002-11-3529
Dudek, A. Z. et al. Platelet factor 4 binds to glycanated forms of thrombomodulin and to protein C. J. Biol. Chem. 272, 31785–31792 (1997).
pubmed: 9395524
doi: 10.1074/jbc.272.50.31785
Amelot, A. A., Tagzirt, M., Ducouret, G., Kuen, R. L., Le & Bonniec, B. F. Platelet factor 4 (CXCL4) seals blood clots by altering the structure of fibrin. J. Biol. Chem. 282, 710–720 (2007).
pubmed: 17090548
doi: 10.1074/jbc.M606650200
Polley, M. J. & Nachman, R. L. Human platelet activation by C3a and C3a des-arg. J. Exp. Med. 158, 603–615 (1983).
pubmed: 6604123
doi: 10.1084/jem.158.2.603
Meuer, S., Ecker, U., Hadding, U. & Bitter-Suermann, D. Platelet-serotonin release by C3a and C5a: two independent pathways of activation. J. Immunol. 126, 1506–1509 (1981).
pubmed: 7204973
doi: 10.4049/jimmunol.126.4.1506
Mizuno, T. et al. Complement component 5 promotes lethal thrombosis. Sci. Rep. 7, 42714 (2017).
pubmed: 28205538
pmcid: 5311936
doi: 10.1038/srep42714
Kwan, W., van der Touw, W., Paz-Artal, E., Li, M. O. & Heeger, P. S. Signaling through C5a receptor and C3a receptor diminishes function of murine natural regulatory T cells. J. Exp. Med. 210, 257–268 (2013).
pubmed: 23382542
pmcid: 3570105
doi: 10.1084/jem.20121525
Ward, PeterA. & Sarma, V. J. New developments in C5a receptor signaling. Cell Health Cytoskelet. 4, 73–82 (2012).
pubmed: 23576881
pmcid: 3619443
doi: 10.2147/CHC.S27233
Lalli, P. N. et al. Locally produced C5a binds to T cell–expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. Blood 112, 1759–1766 (2008).
pubmed: 18567839
pmcid: 2518884
doi: 10.1182/blood-2008-04-151068
Strainic, M. G. et al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 28, 425–435 (2008).
pubmed: 18328742
pmcid: 2646383
doi: 10.1016/j.immuni.2008.02.001
Wrann, C. D. et al. The phosphatidylinositol 3-kinase signaling pathway exerts protective effects during sepsis by controlling C5a-mediated activation of innate immune functions. J. Immunol. 178, 5940–5948 (2007).
pubmed: 17442978
doi: 10.4049/jimmunol.178.9.5940
Bosmann, M., Sarma, J. V., Atefi, G., Zetoune, F. S. & Ward, P. A. Evidence for anti-inflammatory effects of C5a on the innate IL-17A/IL-23 axis. FASEB J. 26, 1640–1651 (2012).
pubmed: 22202675
pmcid: 3316904
doi: 10.1096/fj.11-199216
Rabiet, M. J., Huet, E. & Boulay, F. The N-formyl peptide receptors and the anaphylatoxin C5a receptors: an overview. Biochimie 89, 1089–1106 (2007).
pubmed: 17428601
pmcid: 7115771
doi: 10.1016/j.biochi.2007.02.015
Chatterjee, M. & Gawaz, M. Platelet-derived CXCL12 (SDF-1α): basic mechanisms and clinical implications. J. Thromb. Haemost. 11, 1954–1967 (2013).
pubmed: 24024928
doi: 10.1111/jth.12404
Van Raemdonck, K. et al. Angiostatic, tumor inflammatory and anti-tumor effects of CXCL4(47-70) and CXCL4L1(47-70) in an EGF-dependent breast cancer model. Oncotarget 15, 10916–10933 (2014).
Sarabi, A. et al. CXCL4L1 inhibits angiogenesis and induces undirected endothelial cell migration without affecting endothelial cell proliferation and monocyte recruitment. J. Thromb. Haemost. 9, 209–219 (2011).
pubmed: 20961394
doi: 10.1111/j.1538-7836.2010.04119.x
Herzog, S., Sager, H., Khmelevski, E., Deylig, A. & Ito, W. D. Collateral arteries grow from preexisting anastomoses in the rat hindlimb. Am. J. Physiol. Circ. Physiol. 283, H2012–H2020. (2002).
doi: 10.1152/ajpheart.00257.2002
Ziegler, T. et al. Steerable induction of the thymosin β4/MRTF-A pathway via AAV-based overexpression induces therapeutic neovascularization. Hum. Gene Ther. 29, 1407–1415 (2018).
doi: 10.1089/hum.2017.013
Bodnar, R. J. Chemokine regulation of angiogenesis during wound healing. Adv. Wound Care 4, 641–650 (2015).
doi: 10.1089/wound.2014.0594
Lin, S.-L., Kisseleva, T., Brenner, D. A. & Duffield, J. S. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am. J. Pathol. 173, 1617–1627 (2008).
pubmed: 19008372
pmcid: 2626374
doi: 10.2353/ajpath.2008.080433
Korf-Klingebiel, M. et al. Myeloid-derived growth factor (C19orf10) mediates cardiac repair following myocardial infarction. Nat. Med. 21, 140–149 (2015).
pubmed: 25581518
doi: 10.1038/nm.3778
Ricklin, D., Mastellos, D. C., Reis, E. S. & Lambris, J. D. The renaissance of complement therapeutics. Nat. Rev. Nephrol. 14, 26–47 (2018).
pubmed: 29199277
doi: 10.1038/nrneph.2017.156
Hillmen, P. et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 355, 1233–1243 (2006).
pubmed: 16990386
doi: 10.1056/NEJMoa061648
Kelly, R. J. et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 373, 1032–1039 (2015).
pubmed: 26352814
doi: 10.1056/NEJMoa1502950
Noris, M., Mescia, F. & Remuzzi, G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat. Rev. Nephrol. 8, 622–633 (2012).
pubmed: 22986360
doi: 10.1038/nrneph.2012.195
Rinder, C. S. et al. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J. Clin. Investig. 96, 1564–1572 (1995).
pubmed: 7657827
doi: 10.1172/JCI118195
pmcid: 185782
Laudes, I. J. et al. Anti-C5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Am. J. Pathol. 160, 1867–1875 (2002).
pubmed: 12000738
pmcid: 1850866
doi: 10.1016/S0002-9440(10)61133-9
Ricklin, D. & Lambris, J. D. Complement-targeted therapeutics. Nat. Biotechnol. 25, 1265–1275 (2007).
pubmed: 17989689
pmcid: 2966895
doi: 10.1038/nbt1342
Murayama, M. A. et al. CTRP6 is an endogenous complement regulator that can effectively treat induced arthritis. Nat. Commun. 6, 8483 (2015).
pubmed: 26404464
doi: 10.1038/ncomms9483
Rittirsch, D. et al. Functional roles for C5a receptors in sepsis. Nat. Med. 14, 551–557 (2008).
pubmed: 18454156
pmcid: 2753858
doi: 10.1038/nm1753
Schwaeble, W. J. et al. Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury. Proc. Natl Acad. Sci. USA 108, 7523–7528 (2011).
pubmed: 21502512
doi: 10.1073/pnas.1101748108
pmcid: 3088599
Girardi, G. et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J. Clin. Investig. 112, 1644–1654 (2003).
pubmed: 14660741
doi: 10.1172/JCI200318817
pmcid: 281643
Zhou, H.-f et al. Antibody directs properdin-dependent activation of the complement alternative pathway in a mouse model of abdominal aortic aneurysm [Internet]. Proc. Natl Acad. Sci. USA 109, E415–E422 (2012).
pubmed: 22308431
doi: 10.1073/pnas.1119000109
pmcid: 3289386
Hopken, U. E., Lu, B., Gerard, N. P. & Gerard, C. The C5a chemoattractant receptor mediates mucosal defence to infection. Nature 383, 86–89 (1996).
pubmed: 8779720
doi: 10.1038/383086a0
Mastellos, D., Papadimitriou, J. C., Franchini, S., Tsonis, P. A. & Lambris, J. D. A novel role of complement: mice deficient in the fifth component of complement (C5) exhibit impaired liver regeneration. J. Immunol. 166, 2479–2486 (2001).
pubmed: 11160308
doi: 10.4049/jimmunol.166.4.2479
Kildsgaard, J. et al. Cutting Edge: Targeted disruption of the C3a receptor gene demonstrates a novel protective anti-inflammatory role for C3a in endotoxin-shock. J. Immunol. 165, 5406–5409 (2000).
pubmed: 11067891
doi: 10.4049/jimmunol.165.10.5406
Hancock, W. W. et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J. Exp. Med. 192, 1515–1520 (2000).
pubmed: 11085753
pmcid: 2193193
doi: 10.1084/jem.192.10.1515
von Hundelshausen, P. et al. Chemokine interactome mapping enables tailored intervention in acute and chronic inflammation. Sci. Transl. Med. 9, 1–15. (2017).
Limbourg, A. et al. Evaluation of postnatal arteriogenesis and angiogenesis in a mouse model of hind-limb ischemia. Nat. Protoc. 4, 1737–1748 (2009).
pubmed: 19893509
doi: 10.1038/nprot.2009.185
Qi, X. et al. 2-Hydroxypropyl)-β-cyclodextrin is a new angiogenic molecule for therapeutic angiogenesis. PLoS ONE 10, 1–16 (2015).
Li, Y. et al. The effect of heparin administration in animal models of sepsis: a prospective study in Escherichia coli-challenged mice and a systematic review and metaregression analysis of published studies. Crit. Care Med. 39, 1104 (2011).
pubmed: 21317646
pmcid: 3389754
doi: 10.1097/CCM.0b013e31820eb718
Kumar, V. et al. Preclinical pharmacokinetics of complement C5a receptor antagonists PMX53 and PMX205 in mice. ACS Omega 5, 2345–2354 (2020).
pubmed: 32064396
pmcid: 7017397
doi: 10.1021/acsomega.9b03735
Schaad, L. et al. Correlative imaging of the murine hind limb vasculature and muscle tissue by microCT and light microscopy. Sci. Rep. 7, 41842 (2017).
pubmed: 28169309
pmcid: 5294414
doi: 10.1038/srep41842
Kroes, T., Post, F. H. & Botha, C. P. Exposure render: an interactive photo-realistic volume rendering framework. PLoS ONE 7, e38586 (2012).
pubmed: 22768292
pmcid: 3388083
doi: 10.1371/journal.pone.0038586
Girardi, G., Redecha, P. & Salmon, J. E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat. Med. 10, 1222–1226 (2004).
pubmed: 15489858
doi: 10.1038/nm1121
Abe, T. et al. Local complement-targeted intervention in periodontitis: proof-of-concept using a C5a receptor (CD88) antagonist. J. Immunol. 189, 5442–5448 (2012).
pubmed: 23089394
doi: 10.4049/jimmunol.1202339
Lonsdorf, A. S. et al. Engagement of αIIbβ3 (GPIIb/IIIa) with ανβ3 integrin mediates interaction of melanoma cells with platelets. J. Biol. Chem. 287, 2168–2178 (2012).
pubmed: 22102277
doi: 10.1074/jbc.M111.269811
Assinger, A., Volf, I. & Schmid, D. A novel, rapid method to quantify intraplatelet calcium dynamics by ratiometric flow cytometry. PLoS ONE 10, 1–15. (2015).
doi: 10.1371/journal.pone.0122527
Zaglia, T. et al. Optimized protocol for immunostaining of experimental GFP-expressing and human hearts. Histochem. Cell Biol. 146, 407–419 (2016).
pubmed: 27311322
doi: 10.1007/s00418-016-1456-1
Nording, H. et al. Platelet bound oxLDL shows an inverse correlation with plasma anaphylatoxin C5a in patients with coronary artery disease. Platelets 27, 593–597 (2016).
pubmed: 27025272
doi: 10.3109/09537104.2016.1148807
Langer, H. et al. Adherent platelets recruit and induce differentiation of murine embryonic endothelial progenitor cells to mature endothelial cells in vitro. Circ. Res. 98, e2–e10. (2006).
pubmed: 16373597
doi: 10.1161/01.RES.0000201285.87524.9e
Reis, E. S. et al. C5a receptor-dependent cell activation by physiological concentrations of desarginated C5a: insights from a novel label-free cellular assay. J. Immunol. 189, 4797–4805 (2012).
pubmed: 23041570
doi: 10.4049/jimmunol.1200834
Croker, D. E. et al. Discovery of functionally selective C5aR2 ligands: novel modulators of C5a signalling. Immunol. Cell Biol. 94, 787–795 (2016).
pubmed: 27108698
doi: 10.1038/icb.2016.43
van Triest, M., de Rooij, J. & Bos, J. L. Measurement of GTP-bound Ras-like GTPases by activation-specific probes. Methods Enzymol. 333, 343–348 (2001).
Choi, E. Y. et al. Del-1, an endogenous leukocyte-endothelial adhesion inhibitor, limits inflammatory cell recruitment. Science 322, 1101–1104 (2008).
pubmed: 19008446
pmcid: 2753175
doi: 10.1126/science.1165218
Schönberger, T. et al. Pivotal role of phospholipase D1 in tumor necrosis factor-α-mediated inflammation and scar formation after myocardial ischemia and reperfusion in mice. Am. J. Pathol. 184, 2450–2464 (2014).
pubmed: 25046692
doi: 10.1016/j.ajpath.2014.06.005
Carmona, G. et al. Role of the small GTPase Rap1 for integrin activity regulation in endothelial cells and angiogenesis. Angiogenesis 113, 488–497 (2009).
Fantin, A., Vieira, J. M., Plein, A., Maden, C. H. & Ruhrberg, C. The embryonic mouse hindbrain as a qualitative and quantitative model for studying the molecular and cellular mechanisms of angiogenesis. Nat. Protoc. 8, 418–429 (2013).
pubmed: 23424750
pmcid: 3763679
doi: 10.1038/nprot.2013.015
Zudaire, E., Gambardella, L., Kurcz, C. & Vermeren, S. A computational tool for quantitative analysis of vascular networks. PLoS ONE 6, e27385 (2011).
pubmed: 22110636
pmcid: 3217985
doi: 10.1371/journal.pone.0027385
Luna, R. L. et al. Placental growth factor deficiency is associated with impaired cerebral vascular development in mice. Mol. Hum. Reprod. 22, 130–142 (2016).
pubmed: 26646502
doi: 10.1093/molehr/gav069